A detailed history of Summit Global Investments transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Summit Global Investments holds 29,835 shares of BMY stock, worth $1.24 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
29,835
Previous 38,040 21.57%
Holding current value
$1.24 Million
Previous $1.95 Million 17.11%
% of portfolio
0.12%
Previous 0.13%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

SELL
$47.98 - $54.4 $393,675 - $446,352
-8,205 Reduced 21.57%
29,835 $1.62 Million
Q4 2023

Feb 06, 2024

SELL
$48.48 - $57.85 $6.46 Million - $7.71 Million
-133,210 Reduced 77.79%
38,040 $1.95 Million
Q3 2023

Oct 13, 2023

SELL
$57.89 - $64.73 $5.22 Million - $5.83 Million
-90,096 Reduced 34.47%
171,250 $9.94 Million
Q2 2023

Jul 18, 2023

BUY
$63.71 - $70.74 $1.14 Million - $1.27 Million
17,946 Added 7.37%
261,346 $16.7 Million
Q1 2023

May 04, 2023

BUY
$65.71 - $74.53 $413,710 - $469,240
6,296 Added 2.66%
243,400 $16.9 Million
Q4 2022

Jan 31, 2023

SELL
$68.48 - $81.09 $121,072 - $143,367
-1,768 Reduced 0.74%
237,104 $17.1 Million
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $2,738 - $1.62 Million
-21,063 Reduced 8.1%
238,872 $17 Million
Q2 2022

Aug 23, 2022

SELL
$72.62 - $79.98 $951,322 - $1.05 Million
-13,100 Reduced 4.8%
259,935 $20 Million
Q1 2022

Apr 29, 2022

SELL
$61.48 - $73.72 $4.02 Million - $4.82 Million
-65,419 Reduced 19.33%
273,035 $19.9 Million
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $16.3 Million - $19.1 Million
304,828 Added 906.52%
338,454 $21.1 Million
Q3 2021

Nov 08, 2021

SELL
$59.17 - $69.31 $70,353 - $82,409
-1,189 Reduced 3.42%
33,626 $1.99 Million
Q2 2021

Jan 28, 2022

SELL
$61.91 - $67.42 $524,934 - $571,654
-8,479 Reduced 19.58%
34,815 $2.32 Million
Q1 2021

Jan 27, 2022

SELL
$59.34 - $66.74 $29,907 - $33,636
-504 Reduced 1.15%
43,294 $2.73 Million
Q4 2020

Feb 11, 2021

BUY
$57.74 - $65.43 $132,744 - $150,423
2,299 Added 5.54%
43,798 $2.72 Million
Q3 2020

Nov 16, 2020

SELL
$57.43 - $63.64 $259,411 - $287,461
-4,517 Reduced 9.82%
41,499 $2.5 Million
Q2 2020

Aug 11, 2020

BUY
$54.82 - $64.09 $1.43 Million - $1.67 Million
26,075 Added 130.76%
46,016 $2.71 Million
Q1 2020

May 14, 2020

SELL
$46.4 - $67.43 $8.8 Million - $12.8 Million
-189,716 Reduced 90.49%
19,941 $1.11 Million
Q4 2019

Feb 13, 2020

SELL
$49.21 - $64.19 $5.18 Million - $6.76 Million
-105,246 Reduced 33.42%
209,657 $13.5 Million
Q3 2019

Nov 08, 2019

SELL
$42.77 - $50.71 $2.84 Million - $3.37 Million
-66,494 Reduced 17.43%
314,903 $16 Million
Q2 2019

Aug 16, 2019

BUY
$44.62 - $49.34 $6.36 Million - $7.03 Million
142,532 Added 59.67%
381,397 $17.3 Million
Q1 2019

May 14, 2019

BUY
$45.12 - $53.8 $449,620 - $536,117
9,965 Added 4.35%
238,865 $11.4 Million
Q4 2018

Feb 08, 2019

BUY
$48.76 - $63.23 $10.2 Million - $13.2 Million
208,335 Added 1013.06%
228,900 $11.9 Million
Q3 2018

Nov 15, 2018

SELL
$55.19 - $62.25 $551 - $622
-10 Reduced 0.05%
20,565 $1.28 Million
Q2 2018

Aug 10, 2018

BUY
$50.53 - $62.98 $619,750 - $772,449
12,265 Added 147.59%
20,575 $1.14 Million
Q1 2018

May 03, 2018

BUY
$59.92 - $68.98 $497,935 - $573,223
8,310 New
8,310 $526,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $88.3B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Summit Global Investments Portfolio

Follow Summit Global Investments and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Global Investments, based on Form 13F filings with the SEC.

News

Stay updated on Summit Global Investments with notifications on news.